Artivion (NYSE:AORT) Upgraded at Wall Street Zen

Key Points

• Artivion has been upgraded to a "buy" rating by Wall Street Zen, indicating positive sentiment from analysts regarding the company's stock performance.
• Multiple research firms have raised their price targets for Artivion, with Needham & Company boosting theirs from $45.00 to $50.00, reflecting growing confidence in the stock's potential.
• Artivion reported better-than-expected quarterly earnings, with an EPS of $0.24 compared to analysts' estimates of $0.11, indicating strong financial performance and a year-over-year revenue increase of 15.3%.

Artivion (NYSE:AORT - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Monday.

A number of other brokerages have also recently commented on AORT. Citizens Jmp upgraded Artivion to a "strong-buy" rating in a research report on Tuesday, May 6th. Needham & Company LLC raised their price target on Artivion from $45.00 to $50.00 and gave the company a "buy" rating in a report on Friday, August 22nd. Canaccord Genuity Group raised their price target on Artivion from $35.00 to $41.00 and gave the company a "buy" rating in a report on Friday, August 8th. Oppenheimer restated an "outperform" rating on shares of Artivion in a report on Friday, August 8th. Finally, JMP Securities raised their price target on Artivion from $33.00 to $42.00 and gave the company a "market outperform" rating in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Artivion presently has an average rating of "Buy" and an average price target of $40.63.

Artivion Stock Performance

Artivion stock traded up $0.07 during mid-day trading on Monday, reaching $43.88. 141,074 shares of the stock traded hands, compared to its average volume of 444,160. The stock has a market capitalization of $2.07 billion, a PE ratio of -104.37 and a beta of 1.64. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. Artivion has a 12-month low of $21.97 and a 12-month high of $45.07. The business's 50-day moving average is $34.80 and its 200-day moving average is $29.22.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.13. The company had revenue of $112.97 million during the quarter, compared to analysts' expectations of $107.96 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The business's revenue for the quarter was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Artivion will post 0.37 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Marshall S. Stanton sold 26,132 shares of the company's stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $28.44, for a total value of $743,194.08. Following the completion of the transaction, the senior vice president owned 79,200 shares of the company's stock, valued at approximately $2,252,448. This represents a 24.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John E. Davis sold 10,802 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $43.67, for a total value of $471,723.34. Following the transaction, the insider directly owned 208,778 shares of the company's stock, valued at $9,117,335.26. The trade was a 4.92% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 115,990 shares of company stock worth $4,435,823. 7.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Legacy Advisors LLC acquired a new stake in shares of Artivion during the first quarter worth about $28,000. MCF Advisors LLC increased its position in shares of Artivion by 109.3% during the first quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock worth $29,000 after purchasing an additional 614 shares in the last quarter. Smartleaf Asset Management LLC increased its position in shares of Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock worth $52,000 after purchasing an additional 538 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Artivion during the fourth quarter worth about $64,000. Finally, Tower Research Capital LLC TRC increased its position in shares of Artivion by 447.6% during the second quarter. Tower Research Capital LLC TRC now owns 5,410 shares of the company's stock worth $168,000 after purchasing an additional 4,422 shares in the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.